QXL138AM
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- Nammi Therapeutics Inc
- Tags
- CD138
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1984
- NCT Identifier
- NCT06582017
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.